ArticleInfectious diseases and therapy2021

Addressing HCV Elimination Barriers in Italy: Healthcare Resource Utilization and Cost Impact Using 8 Weeks' Glecaprevir/Pibrentasvir Therapy.

Massimo Andreoni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.